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Background: The aim of the current study is to investigate the effect of leptin on 
cytoskeleton structures in both in vivo and in vitro model of diabetes. 
Materials and methods: For in vivo studies, leptin in different doses (240, and 
480 mg/kg) was injected to the diabetic rats after 1-week of streptozotocin (STZ, 
55 mg/kg) treatment. Leptin levels were analysed in serum, liver, and pancreas 
samples. Hepatic and pancreatic F- and G-actin expressions were determined by 
Western blotting. For in vitro studies, hepatic and pancreatic primary cell lines 
were obtained from the control rats. To these cultures, STZ (15 and 30 mM), 
leptin (50, 60 and 100 ng/mL), and their combinations were applied for 1, 3, 
and 4 weeks. After the treatment period, F-actin was visualised by the Alexa-fluor 
fluorescent dye. 
Results: Streptozotocin decreased the G-actin in both tissues in vivo. However, 
leptin caused a dose-dependent increase in G-actin levels while F-actin decreased 
in both tissues. Moreover, leptin caused the perimembranous condensation of 
actin filaments and amelioration of F-actin structures in vivo. A dose-dependent 
corruption of F-actin filament structures was observed in leptin-treated primary 
cells in vitro, while STZ also caused corruption of these filaments. Co-exposure 
of STZ and leptin caused the amelioration of F-actin filaments, while the peri-
membranous condensation was also observed as was in vivo study. 
Conclusions: Leptin therapy could be a candidate for diabetes, but it should not 
be ruled out as being important the severity of diabetes and leptin doses. (Folia 
Morphol 2019; 78, 2: 314–324)
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INTRODUCTION
Diabetes mellitus (DM) is one of common disease 
worldwide. In 2014, it was reported that 7.5% of 
women and 5% of men face to DM. The prevalence 
is expected to reach 439 million by 2030 meaning 
of total 7.7% adult population between 20 and 79 
years [43]. There are two types of DM. One of this 
called type 1 associated with the increased blood glu-
cose due to insufficient production of insulin in the 
body. Insulin insensitivity of the cells causes type 2, 
and the body produces sufficient insulin in this cases. 
Therefore, it is essential to find effective strate-
gies to manage or control the prevalence of DM. 
Herein, leptin takes great attention in the control 
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of hyperglycaemia and/or hyperglycemia-induced 
dysfunctions. 
Leptin, a protein hormone, affects the body weight, 
energy metabolism, reproductive system, and the neu-
roendocrine system [24]. Furthermore, the hormone 
plays a significant role in insulin-glucose homeostasis 
in the pancreas, liver, muscle, and hypothalamus as 
well. Insulin stimulates leptin secretion [38]. Leptin has 
acted centrally in the hypothalamus and peripherally 
in the pancreas, muscle, and liver. Leptin also improves 
glucose-insulin metabolism via attenuating glycemia, 
insulinemia, and insulin resistance
To develop leptin-based therapies against diabe-
tes, and other insulin resistance syndromes, leptin’ 
effect on the glucose-insulin homeostasis should be 
understood well [38]. There is a complicated rela-
tionship between insulin resistance and leptin. For 
example, leptin may increase insulin sensitivity and 
improve the glucose metabolism [38]. Also, a previous 
study indicated that insulin resistance was amelio-
rated by administration of leptin in mice [6]. Hence, 
it was proposed that the leptin plays a possible role 
in insulin resistance and it can improve insulin pro-
duction [6]. Insulin resistance can be described as 
insufficiency in the insulin pathway at target tissues 
which generally response, like adipose, liver, skeletal, 
and heart muscle [2]. 
The cytoskeleton is essential to keep cell shape 
and signalling pathways for the beta (b) cells. The 
perturbation of actin structures might give rise to 
enhance b cell dysfunction, including inflammation and 
fibrosis [1]. Actin plays a vital function in morphology, 
migration, adhesion, and permeability [33]. Actin is 
abundant and highly conserved proteins among species. 
It is a member of structural superfamily sugar kinases 
hexokinases and Hsp70 proteins [10]. Actin is one of the 
cytoskeleton element and has many essential roles in 
cells such as cell shape, polarity, endocytosis, contractil-
ity, motility, intracellular trafficking, etc. Actin has two 
form of monomeric G-actin and filamentous polymeric 
F-actin [46]. G-actin can be converted to F-actin by the 
presence of adenosine three phosphate (ATP), ions, 
actin-binding proteins. F-actin and myosin interaction 
cause muscle contraction. The primary control factor of 
transformation is nucleotide hydrolysis [10]. Conversion 
of G-actin to the filamentous form participates in patho-
logical processes, such as cancer metastasis as well [50]
There is little knowledge available on the relation-
ship between insulin and leptin. The current study 
was aimed to evaluate how F-actin structure can be 
affected by leptin therapy in streptozotocin (STZ)-
-induced diabetic rats in both in vivo and in vitro 
conditions. To our knowledge, it is the first study 
to investigate the effects of leptin on cytoskeleton 
structures of the STZ-treated cells and animals.
MATERIALS AND METHODS
Experimental animals
Male Wistar rats weighing between 140 and 
250 g were purchased from the Faculty of Veterinary 
Medicine, Department of Reproduction and Artificial 
Insemination, Istanbul University. The animals were 
individually housed in stainless cages at 20 ± 2°C, 
60–70% humidity with 12:12 h photoperiod. Water 
and food were given ad libitum. All processes were 
approved by the Istanbul University Animal Welfare 
Committee.
Induction of experimental diabetes
Diabetes was induced by STZ. Streptozotocin was 
freshly prepared in a citrate buffer (50 mM, pH 4.5). 
Control group received only citrate buffer as a vehicle. 
55 mg/kg of STZ was injected the intraperitoneally to 
rats [42]. One week after STZ injection, animal having 
blood glucose levels ≥ 250 mg/dL was accepted as 
diabetic [27]. The blood glucose levels were measured 
by using a glucometer (OneTouch Ultra; LifeScan, 
Milpitas, CA, USA) from orbital vein blood samples. 
In vivo experimental design
Four groups were randomly carried out as 
(I) control (C group): non-diabetic rats treated with 
the vehicle, (II) diabetes (D group): diabetic rats 
treated with the vehicle, (III) diabetes+leptin 240 
(DL240 group): diabetic rats treated with 240 ng/
kg dose of leptin, (IV) diabetes+leptin 480 (DL480 
group): diabetic rats treated with 480 ng/kg dose of 
leptin (modified from [47]). Both doses are physio-
logic doses of leptin [31]. Experimental animals were 
treated with the leptin every other day for 1 week. 
C group received intraperitoneally physiological 
saline as the same volume of DL group. Four ex-
perimental animals were used for each group. After 
treatments periods, liver and pancreas were removed 
from experimental animals for F- and G-actin analysis 
by Western blotting. Body weights were measured 
at two time points: at the beginning of the first in-
jection and 24 h after the last injection. Then, body 
weight gain was calculated by subtracting from the 
last day to the first day of the experiment.
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In vitro experimental design
For in vitro studies, primary hepatic (modified 
from [28]) and pancreatic cells (modified from [21]) 
were isolated from the corresponding tissues of the 
C group. Hepatic primary cells were recognised as 
parenchyma and Kupffer. The liver was removed 
aseptically and washed with Hanks’ balanced salt 
solution (HBSS). Then, the tissues were minced into 
1-mm3 pieces in HBSS. The cells were suspended 
in William’s Medium E (WME) and centrifuged for 
5 min at 3000 g and the supernatant discarded. 
Cells were dissolved in WME and transferred into 
an incubator with 5% CO2 atmosphere at 37°C. For 
pancreatic acinar primary cell culture, each pancreas 
was minced into 1 mm3 piece and incubated with 
2 mL of HBSS with 2 M EDTA at 37°C for 15 min. 
The chelated mixture was centrifuged for 5 min at 
3000 g, and the supernatant was discarded. The 
pellet was rinsed with 10 mL Ham’s F-12 medium, 
centrifuged for 5 min at 3000 g, and the supernatant 
discarded. The tissue pellet digested with 10 mL of 
1 mg/mL collagenase type II, 1 mg/mL hyaluronidase 
and 20% heat-inactivated calf serum in Ham’s F-12 
medium at 37°C for 30 min in a shaking water bath. 
Following centrifugation at 3000 g for 5 min, the 
supernatant discarded, pellet rinsed with 10 mL of 
HBSS, and this procedure was replicated. The cells 
were rinsed with 5% heat-inactivated calf serum in 
Ham’s F-12 medium and centrifuged at 3000 g for 
10 min. The pellet rinsed with 10 mL of 5% heat-
inactivated calf serum in Ham’s F-12. Cells allocated 
to a well containing 2 mL of Waymouth’s serum-free 
medium and incubated at 37°C with 5% humidified 
CO2 for 48 h.
The hepatic and pancreatic cells from non-dia-
betic control rats were divided into four groups as 
control (c group), STZ (S group), leptin (L group), 
and STZ+leptin (SL group) for 1 and 4 weeks. Like 
hepatic cells, the pancreatic cells were also divided 
into four groups. To observe the effect of severity of 
hyperglycaemia, the cell lines were treated with two 
different doses of STZ as 15 or 30 mM. To determine 
the effect of different doses of leptin on cell lines, 
50, 60 and 100 ng/mg of leptin were injected into 
the cells. The hepatic cells were treated with the 
leptin for 1 and 4 weeks. The pancreatic cells were 
treated with the leptin for 3 weeks. The data from 
DL groups in the pancreatic cells were not obtained 
because of lower cell numbers although the medium 
was replaced 2 times a week. 
F-actin organisation
Immunofluorescence microscopy was used to 
determine F-actin organisation in both in vitro (the 
primary cell cultures) and in vivo (cryosections of 
liver and pancreas) [17]. Briefly, primary culture cells 
were fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 10 min at room temperature 
and then permeabilised and blocked in PBS con-
taining 0.1% Triton X-100 and 5% foetal calf serum 
for 30 min. Actin filaments were visualised using 
rhodamine-phalloidin or Alexa 497, and nuclei were 
labeled with 4’,6-diamidino–2–phenylindole dichlo-
ride (DAPI) (Invitro Molecular Probes, OR, USA). All 
images were obtained using an Olympus BX51 Mi-
croscope equipped with a DP72 camera controlled 
by Olympus DP2-TWAIN software. 
Western blotting
In vivo, F- and G-actin proteins were isolated 
from the pancreas and liver tissues. Tissues were ho-
mogenised by a MagNA lyser (Roche Diagnostics). 
Aliquots of liver and pancreas homogenates were 
centrifuged at 3000 g for 15 min and 4500 g for 
20 min, respectively. F- and G-actin were separated 
by a kit (Cytoskeleton, Cat #BK037) according to 
the manufacturer’s instruction [26]. Then, 50 µg 
F- or G-actin were loaded to SDS–PAGE and trans-
ferred to a PVDF membrane (Millipore Corporation, 
Bedford, MA, USA) at 100 V for 45 min. The mem-
branes were blocked by using 5% bovine serum 
albumin. Membranes were incubated with anti-
actin rabbit polyclonal antibody (1/500) at +4℃ for 
overnight (Abcam, USA), and then incubated with 
a horseradish peroxidase-conjugated goat anti-
rabbit IgG antibody for 1 h at room temperature. 
5-bromo-chloro-3-indol phosphate (BCIP) was used 
for visualisation for protein band. After membranes 
were photographed with Canon camera, ImageJ 
was used to analyse the band.
Leptin analysing
Blood and homogenates of liver and pancreas 
were centrifuged at 10,000 g for 15 min at +4°C. 
Leptin levels were measured by ELISA using a com-
mercial assay kit according to the manufacturer’s 
directions (Millipore, USA) [7].
Statistical analysis
The analyses of statistical were performed by SPSS 
version 23.0. Data are expressed as mean ± standard 
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error of the mean (SEM). One-way analysis of vari-
ance (one-way ANOVA) with post hoc Tukey for equal 
variance assumed and post hoc Dunnett’T3 for equal 
variance not assumed were used to compare mean 
between the groups. P < 0.05 was accepted as the 
statistical significance.
RESULTS
Effect of leptin on body weight and blood  
glucose level
Diabetes decreased significantly body weight gain 
in D groups when compared to the C group (p < 0.05). 
The treatment of leptin failed to control body weight 
gain in diabetic rats. Interestingly, 240 ng/kg of leptin 
non-significantly worsen the body weight gain in 
DL240 group compared to the D group. But, there 
were no significant differences in body weight gain 
among D, DL240, and DL480 groups (Fig. 1). 
Blood glucose level is a primary parameter to de-
termine diabetes. The delta was calculated by subtrac-
tion of glucose levels before and after experiments. 
As expected, all diabetes groups had high blood 
glucose level and the delta compared to C group 
after STZ injection (p < 0.05). Leptin treatment did 
not improve the high blood glucose when compared 
to D group (Fig. 2). 
The leptin levels were measured in serum, liver 
and pancreas samples. Diabetes did not influence the 
leptin levels in serum, pancreas, and liver in contrast 
to C group. Also, leptin treatment in all dose signifi-
cantly increased the serum leptin levels compared to 
D group as expected (p < 0.01). The doses of leptin 
higher than 240 ng/kg significantly increased the se-
rum leptin levels in contrast to D and DL240 groups 
(p < 0.01). However, the treatment of diabetic rats 
with leptin did not affect the level of leptin in liver 
and pancreas when compared to D group (Fig. 3).
The effect of leptin on actin structure 
The actin structure is so crucial for glucose me-
tabolism. Therefore, it was evaluated the F-actin dis-
tribution of liver and pancreas tissues in vivo and 
pancreas primary acinar, Kupffer and parenchymal 
also called as hepatocyte cells in vitro, as well.
For in vivo studies, diabetes induction gave rise 
to disrupt F-actin structure in liver tissues. The treat-
ment of diabetic rats with 240 ng/kg dose of leptin 
improved F-actin in DL240 group when compared to 
D group; however, as the dose of leptin (480 ng/kg, 
DL480) increases, it worsens the effect of diabetes 
on F-actin (Fig. 4A–D). In pancreatic tissue, while 
diabetes also has a destructive impact on the F-actin 
structure in D group compared to C group, the leptin 
treatment in all doses had the protective effect on 
F-actin structure compared to D group (Fig. 4E–H). 
To evaluate the effect of leptin treatment on differ-
ent cell types, parenchymal and Kupffer cells were 
also isolated from rats in C, D and DL240 groups. 
Based on cell types, the effects of leptin on F-actin 
Figure 1. Body weight gain; C — control; D — diabetes; 
DL240 — diabetic rats treated with 240 ng/kg dose of leptin; 
DL480 — diabetic rats treated with 480 ng/kg dose of leptin; 
*p < 0.01; different from C group.
Figure 2. Blood glucose level; C — control; D — diabetes; 
DL240 — diabetic rats treated with 240 ng/kg dose of leptin; 
DL480 — diabetic rats treated with 480 ng/kg dose of leptin; 
*p < 0.01; different from C group.
Figure 3. Leptin levels in serum, pancreas, and liver; C — control; 
D — diabetes; DL240 — diabetic rats treated with 240 ng/kg dose 
of leptin; DL480 — diabetic rats treated with 480 ng/kg dose of 
leptin; *p < 0.01; different from D group.
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showed differences. In the parenchymal cells, F-actin 
disappeared in the cytosol (Fig. 5B, C) whereas slight 
destruction was observed in Kupffer cells (Fig. 5E, F).
Isolated primary cell cultures were preferred to 
reduce the number of animals used in the experiment. 
In primary liver cells, only 100 ng/mL dose of leptin 
(higher dose) was destructive on F-actin structure 
(Fig. 6G–I); therefore, the treatment of the cell with 
the leptin was not continued after 3 weeks. When 
compared to 100 ng/mL dose of leptin, 50 ng/mL 
dose of leptin was not so destructive to the F-actin 
structure in the isolated liver cells. In pancreas cells, 
the detrimental effect of leptin on F-actin was only 
observed at the dose of 60 ng/mL (Fig. 7C, D). In the 
present study, the effect of leptin on F-actin structure 
in STZ-induced pancreatic cells (SL group) were not 
evaluated due to high toxicity of STZ on pancreatic 
cells (Fig. 7E, F) because the cells were exposed to 
STZ at the beginning of the study and F-actin de-
struction was measured after three and/or 4 weeks. 
That indicates the highly destructive effects of STZ 
on the pancreas.
Figure 4. The leptin effect on F-actin distribution from liver and pancreas tissues; liver tissues were as from A to D, although pancreas tissues 
were from E to H; A and E. Control; B and F. Diabetes; C and G. Diabetic rats treated with 240 ng/kg dose of leptin; D and H. Diabetic rats 
treated with 480 ng/kg dose of leptin. 
Figure 5. F-actin distribution of primary liver cells at parenchymal (upper line) and Kupffer cells (below line); red colour represents F-actin, 
blue represents the nucleus by DAPI at ×100 magnification. Parenchymal cells: A and D. Control; B and E. Diabetes; C and F. Diabetic rats 
treated with 240 ng/kg dose of leptin. 
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Figure 6. The leptin effect on F-actin distribution after 3 weeks treated on primary liver cells; A, B, C. Control; D, E, F. Cells treated with  
50 ng/mL dose of leptin; G, H, I. Cells treated with 100 ng/mL dose of leptin (Panels C, F, I is at 20 magnification, and the other is at 100  
magnification).
Figure 7. The leptin effect on F-actin distribution at primary pancreas cells at 100 magnification; A, B. Control; C, D. Cells treated with 60 ng/mL  
dose of leptin; E, F. Cells treated with 30 doses of mM streptozotocin (magnification × 100). 
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Also, the effects of leptin on F-actin structures in 
the primary hepatic cells were studied based on the 
severity of hyperglycaemia or diabetic condition. At 
the mild diabetic condition (15 mM STZ), filopodia 
formation by hyperglycaemia (Fig. 8B1, 8B2) was 
reversed by leptin treatment without any protection 
on the F-actin structure after 4 weeks in both at pa-
renchymal and Kupffer (Fig. 8D1, 8D2). Leptin failed 
to improve F destruction and filopodia formation 
(Fig. 8E1, 8E2); both induced by severe diabetic condi-
tion (30 mM STZ; Fig. 8C1, 8C2).
The effect of leptin treatment on F- and G-actin 
protein expression 
Leptin treatment showed a protective effect on 
disproportional F- and G-actin protein expressions 
compared to diabetes groups in both liver and pan-
creas tissues in vivo (Fig. 9A–D).
DISCUSSION
Cytoskeleton plays a vital role in the cell morphol-
ogy and the elasticity [14]. Insulin can tonically regu-
late actin filament network and microtubule as well 
[35, 51]. Actin network mediates glucose transport 
through insulin action [51]. Actin phosphorylation 
alters cytoskeleton re-orientation via polymerisation 
and depolymerisation [14]. Insulin stimulates leptin 
secretion [38]. Leptin is considered as an anti-diabetic 
hormone. It plays a significant role in glucose ho-
meostasis in the pancreas, liver, muscle, and hypo-
thalamus. Also, it blocks glucose production in the 
liver and enhances glucose consumption in the tissue 
[37]. It was reported that the effects of leptin were 
mediated via the JAK/STAT signalling pathways. b-cells 
are hyperpolarised via ATP sensitive potassium chan-
Figure 8. The leptin effect on F-actin distribution at parenchymal 
(A1, B1, C1, D1, E1) and Kupffer (A2, B2, C2, D2, E2) cells after 
4 weeks treatment; A1, A2. Control; B1, B2. Cells treated with 
15 mM of streptozotocin; C1, C2. Cells treated with 30 mM of 
streptozotocin, D1 and D2) 15 mM exposed cells treated with 60 ng 
leptin E1 and E2) 30 mM exposed cells treated with 60 ng leptin.
Figure 9. The alternation of F- and G-actin protein expression in pancreas and liver tissue; 1. Control; 2. Diabetes; 3. Diabetic rats treated  
with 240 ng/kg dose of leptin; 4. Diabetic rats treated with 480 ng/kg dose of leptin; 5. Diabetic rats treated with 720 ng/kg dose of leptin;  
6. Diabetic rats treated with 960 ng/kg dose of leptin; A. F-actin of the liver; B. G-actin of the liver; C. F-actin of the pancreas; D. G-actin of 
the pancreas.
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nel (KATP) opening by leptin; actin cytoskeleton reor-
ganises through the PI3K pathway [34]. STZ causes 
hyperphagia, hyperleptinaemia, hypoinsulinaemia, 
and hyperglycaemia [40]. Insulin can secrete leptin 
from adipose tissue, controversy; leptin suppresses 
insulin secretion from pancreatic b-cells by activation 
of KATP. Leptin is reported to increase KATP trafficking 
to enhance the channel density on the membrane by 
strengthening F-actin depolymerisation. The traffick-
ing of KATP by leptin is mediated through AMPK and 
protein kinases-A (PKA) [4].
In the present study, diabetes did not affect the 
serum, liver and pancreatic leptin levels. However, 
leptin treatment elevated only the serum leptin levels 
in diabetic rats without altering the pancreatic and 
liver levels. Our results are an inconsistency with the 
previous study, which indicates that increased plasma 
insulin levels due to increased insulin resistance could 
elevate the pancreatic leptin levels [41]. The result of 
the present study demonstrates that leptin did not im-
prove blood glucose level in diabetes. Inconsistently, 
it was reported that a high dose of leptin ameliorated 
the both of hyperlipidaemia and hyperglycaemia [11, 
20]. Co-treatment of leptin and insulin could be more 
useful to prevent hyperglycaemia than insulin only 
therapy, which reduces blood glucose to undesirable 
levels. One advantage of leptin is without to gain 
weight in the treatment of type 1 DM while making 
a balance of blood glucose. An extensive research 
report that type 1 DM reduces body weight [11, 23] 
as reported in the present study. It is probably that 
type 1 DM causes dehydration, declining glucose uti-
lisation and protein anabolism [10]. Leptin provides 
a link between body weight and food intake [5, 49]. 
A correlation between serum leptin levels, plasma 
insulin, and body mass index has been reported [49]. 
Leptin in high concentrations causes insulin resistance 
[49]. In the present study, diabetic rats lose the body 
weight as stated in the previous study [9]. While leptin 
treatment seems to be protective, it was considered 
that weight gain in leptin-treated groups looks like 
developing type 2 DM as was explained in below. Lep-
tin antagonizes the effect of insulin on glucokinase 
and phosphoenolpyruvate carboxylase enzymes to 
decrease blood glucose levels in the liver. A decrease 
in leptin efficiency is related to insulin resistance 
in type 2 DM [36]. Insulin secretion occurs in two 
phases. One phase called fast secretion requires glu-
cose entry to the b-cells, and this leads to the closure 
of ATP sensitive potassium channel (KATP) resulting in 
depolarisation [8]. Finally, insulin secretion occurs. 
The second phase is essential to maintain the insulin 
level in plasma [8]. This phase is associated with the 
reserved pool, which is far away from the plasma 
membrane [12]. Reserved insulin granules must be 
transported to the plasma membrane [8]. F-actin is 
vital to maintaining basal plasma insulin levels [22]. 
Therefore, actin cytoskeleton plays a significant role 
in both phases of insulin secretion [12]. In the current 
study, diabetes caused a decrease of G-actin, while 
any effect was observed on F-actin in vivo. This effect 
can be explained that glucose enhances F- or G-actin 
ratio which means that hyperglycaemia can inhibit 
G-actin disassociation by partial stimulation of cofilin 
phosphorylation. Cofilin belongs to one of actin-
depolymerising factor family and can be inactivated 
with phosphorylation by LIM kinase, causing F-actin 
stabilisation [19]. Rho-A could participate in this path-
way [48]. Diabetes is well known as an autoimmune 
disease. Macrophages inhibit Rho pathways caused 
to disrupt of the cytoskeleton from subcortical actin 
ring to near the cell periphery [13]. G-actin is needed 
for F-actin resembling. Therefore; F-actin maintains its 
proper function. It was proposed that attenuation of 
G-actin participate in the development of diabetes.
Furthermore, F-actin reorientation was observed 
the at the plasma membrane surrounding in the 
current study. F-actin can be depolymerised and scav-
enged by the action of gelsolin, which is one of the 
free calcium regulators, resulting in blood glucose at-
tenuation via the blockage of insulin vesicle transport 
to the membrane [10]. It was suggested that a high 
plasma glucose level could induce actin cytoskeleton 
disruption [22]. This is asserted to relate apoptotic 
cell death [25]. That is why F-actin could release from 
cell to plasma when cell injury is occurred [10]. Leptin 
is also reported to activate LIM kinase for phospho-
rylation of cofilin, resulting in accumulation F-actin 
and depletion of G-actin. The other effect of leptin 
on actin is up-regulation of alpha-skeletal actin and 
myosin light chain-2 (MLC-2) [16].
Insulin and leptin have anti-apoptotic and prolif-
erative effects [39]. Furthermore, leptin was shown 
to have a positive impact on glucose metabolism, 
and it was an excellent adjuvant candidate for insulin 
therapy [44]. Leptin enhanced the insulin sensitivity 
in rats with type 2 DM and patients with type 2 as 
well. A single administration of leptin ameliorated the 
mortality related to high blood glucose and insulin 
independent insulin deficiency [15]. Leptin is shown 
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its anti-diabetic effect via increasing insulin receptor 
sensitivity. However, the involvement of F-actin in 
the mechanism of leptin on type-1 DM is not clearly 
evaluated. Diabetes and leptin therapy showed their 
destructive effect on F-actin according to cell type in 
the current study in vitro. F-actin disappeared from 
cytosol center and accumulated within the periphery 
of the cell membrane in primary parenchymal cells.
On the contrary, F-actin clustered within the cyto-
sol center as multicentered radiant groups in Kupper 
primary cells. In primary pancreas cells, the destruc-
tion process in actin filament is similar to Kuppfer 
primary cell. It was shown that leptin binding to its 
receptor (Ob-Rb) phosphorylates JAK2 and transforms 
PIP2 into PIP3. This destroys the F-actin into the G-actin 
[18]. One study is reported that RhoA and ROCK are 
mediated leptins effect on F-actin distribution. Leptin 
is suggested to enhance the expression and activities 
of GLUT2 and GLUT5 transporters [30]. Leptin has 
been reported to improve insulin sensitivity in both 
healthy and diabetic animals. However, the hormone 
is also said to destroy insulin effect on hepatocytes. 
Leptin infusion is an essential factor for disclosing its 
effect on tissue. Leptin is suggested to decrease blood 
glucose and insulin level without altering body weight 
of animals by subcutan infusion. Leptin intravenously 
injection boosts inulin sensitivity in healthy animals, 
increase glucose consumption in diabetic animals. 
STZ destroy pancreatic b-cell and decrease adipose 
and plasma leptin levels. Therefore, leptin therapy can 
mimic insulin action by insulin-independent and an 
insulin-sensitising mechanism in STZ treated animals. 
Leptin has been shown to activate KATP, resulting in 
decreasing insulin secretion [3].
Cell skeleton is a dynamic and sensitive system. It is 
pointed out as an important morphologic parameter 
in the study of changes that took place in the cell 
after getting into reaction with substance [29]. Some 
vesication is formed within the whole cell during the 
process of cell skeleton’s restructuring. This incidence 
of vesication that took place outside the cell goes 
along both with the distribution of microtubules [45] 
and actin filaments’ restructuring. Actin polymerisa-
tion occurs at G1 and G2/M phases of the cell cycle 
[32]. In actin polymerisation, F- or G-actin rates show 
cellular separation (differentiation) [32].
CONCLUSIONS
The in vivo protective effect of leptin treatment on 
the F-actin structure in both liver and pancreas tissues 
has been presented in the current study. However, 
leptin could not significantly improve F-actin orienta-
tion in vitro in different cell types. A slight improve-
ment of F-actin orientation was observed in Kupffer 
cells compared to parenchymas. Leptin at the higher 
doses can contribute to the destructive effects of dia-
betes. Filopodia formation can be reversed by leptin 
treatment without changing the F-actin destruction 
according to the severity of diabetic conditions. In 
conclusion, leptin treatment could be useful when 
the severity of diabetes and leptin doses are taken 
into consideration. 
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